StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Wednesday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

NASDAQ:EGRX opened at $0.65 on Wednesday. Eagle Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $9.10. The firm’s 50-day moving average is $1.87 and its 200-day moving average is $3.67.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after acquiring an additional 2,630 shares during the period. Headlands Technologies LLC lifted its stake in Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares during the period. Mackenzie Financial Corp acquired a new stake in Eagle Pharmaceuticals during the second quarter valued at approximately $60,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter valued at approximately $65,000. Finally, Fidelis Capital Partners LLC bought a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter valued at approximately $71,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.